Not Yet RecruitingPhase 2

Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

China230 participantsStarted 2026-06-01

Plain-language summary

This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer or advanced kidney cancer.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Histologically or cytologically confirmed diagnosis of HCC, or clinical diagnosis of HCC as per American Association for the Study of Liver Diseases (AASLD) criteria
✓. 4\. Barcelona Clinic Liver Cancer (BCLC) Stage C, or BCLC Stage B that is not suitable for any curative surgeries or locoregional therapy
✓. Child-Pugh Liver Function Class A or Class B (score ≤ 7)
✓. Documented first-line standard treatment failure (disease progression or intolerance)；

What they're measuring

Efficacy of WGI-0301 in Combination with Nivolumab

Timeframe: 24 months

Trial details

NCT IDNCT07494435

SponsorZhejiang Haichang Biotech Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-06-01

Contact for this trial

Angela Men

240-702-0080 angela.men@thewogroup.com

View on ClinicalTrials.gov More Hepato Cellular Carcinoma (HCC) trials